Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer


      Math Eq: To compare the preliminary biochemical relapse-free survival rates between short-course intensity-modulated radiotherapy (SCIM-RT) delivering 70 Gy in 28 fractions and three-dimensional conformal radiotherapy (3D-CRT) delivering 78 Gy in 39 fractions.
      Math Eq: Between January 1998 and December 1999, 166 patients were treated with SCIM-RT and 116 with 3D-CRT. The SCIM-RT cases were treated to 70 Gy (2.5 Gy/fraction) using 5 intensity-modulated fields using a dynamic multileaf collimator. The BAT transabdominal ultrasound system was used for localization of the prostate gland in all SCIM-RT cases. The 116 3D-CRT cases were treated to 78.0 Gy (2.0 Gy/fraction). The study sample therefore comprised 282 cases; 70 Gy in 28 fractions is equivalent to 78 Gy in 39 fractions for late-reacting tissues, according to the linear-quadratic model. The median follow-up for all cases was 25 months (range 3–42). The median follow-up was 21 months for the SCIM-RT cases (range 3–31) and 32 months for the 3D-CRT cases (range 3–42). The follow-up period was shorter for the SCIM-RT cases, because SCIM-RT was started only in October 1998. Biochemical relapse was defined as 3 consecutive rising prostate-specific antigen levels after reaching a nadir. The analysis was then repeated with a more stringent definition of biochemical control: reaching and maintaining a prostate-specific antigen level of ≤0.5 ng/mL. Radiation Therapy Oncology Group toxicity scores were used to assess complications.
      Math Eq: For the 282 patients, the biochemical relapse-free survival rate at 30 months was 91% (95% confidence interval 88–95%). The biochemical relapse-free survival rate at 30 months for 3D-CRT vs. SCIM-RT was 88% (95% confidence interval 82–94%) vs. 94% (95% confidence interval 91–98%), respectively. The difference was not statistically significant between the two treatment arms (p = 0.084). The multivariate time-to-failure analysis using the Cox proportional hazards model for clinical parameters showed the pretreatment prostate-specific antigen level (p <0.001) and biopsy Gleason score (p <0.001) to be the only independent predictors of biochemical relapse. Clinical T stage (p = 0.66), age (p = 0.15), race (p = 0.25), and neoadjuvant androgen deprivation (p = 0.66) were not independent predictors of biochemical failure. SCIM-RT showed only a trend toward a better outcome on multivariate analysis (p = 0.058). Late rectal toxicity was limited; the actuarial combined Grade 2 and 3 late rectal toxicity rate at 30 months was 5% for SCIM-RT vs. 12% for 3D-CRT (p = 0.24). Grade 3 late rectal toxicity (rectal bleeding requiring cauterization) occurred in a total of 10 patients. The actuarial Grade 3 late rectal toxicity rate at 30 months was 2% for the SCIM-RT cases and 8% for the 3D-CRT cases (p = 0.059). Late urinary toxicity was rare in both groups.
      Math Eq: With the currently available follow-up period (≤30 months), the hypofractionated intensity-modulated radiotherapy schedule of 70.0 Gy delivered at 2.5 Gy/fraction had a comparable biochemical relapse profile with the prior 3D-CRT schedule delivering 78.0 at 2.0 Gy/fraction. The late rectal toxicity profile has been extremely favorable. If longer follow-up confirms the favorable biochemical failure and low late toxicity rates, SCIM-RT will be an alternative and more convenient way of providing dose escalation in the treatment of localized prostate cancer.


      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hanks G.E.
        Conformal radiotherapy for prostate cancer.
        Ann Med. 2000; 32: 57-63
        • Kupelian P.A.
        Improvement in overall survival for patients with localized prostate cancer with higher than standard radiation doses.
        J Urol. 1999; 161: 386
        • Kupelian P.A.
        • Buchsbaum J.C.
        • Reddy C.A.
        • et al.
        Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10).
        Int J Radiat Oncol Biol Phys. 2001; 50: 621-625
        • Kupelian P.A.
        • Mohan D.S.
        • Lyons J.
        • et al.
        Higher than standard radiation doses (72 Gy or greater) with or without androgen deprivation in the treatment of localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2000; 46: 567-574
        • Zelefsky M.J.
        • Leibel S.A.
        • Gaudin P.B.
        • et al.
        Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.
        Int J Radiat Oncol Biol Phys. 1998; 41: 491-500
        • Lyons J.A.
        • Kupelian P.A.
        • Mohan D.S.
        • et al.
        Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate.
        Urology. 2000; 55: 85-90
        • Brenner D.J.
        • Hall E.J.
        Fractionation and protraction for radiotherapy of prostate carcinoma.
        Int J Radiat Oncol Biol Phys. 1999; 43: 1095-1101
        • D’Souza W.D.
        • Thames H.D.
        Is the alpha/beta ratio for prostate cancer low?.
        Int J Radiat Oncol Biol Phys. 2001; 51: 1-3
        • Duchesne G.M.
        • Peters L.J.
        What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy.
        Int J Radiat Oncol Biol Phys. 1999; 44: 747-748
        • King C.R.
        • Fowler J.F.
        A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low.
        Int J Radiat Oncol Biol Phys. 2001; 51: 213-214
        • Mohan D.S.
        • Kupelian P.A.
        • Willoughby T.R.
        Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland.
        Int J Radiat Oncol Biol Phys. 2000; 46: 575-580
        • Kupelian P.A.
        • Willoughby T.R.
        Short-course intensity-modulated radiotherapy for localized prostate cancer.
        Cancer J Sci Am. 2001; 7: 421-426
        • Pollack A.
        • Zagars G.K.
        • Smith L.G.
        • et al.
        Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer.
        J Clin Oncol. 2000; 18: 3904-3911
        • D’Amico A.
        Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer.
        Urology. 2001; 58: 78-82
        • Wei J.T.
        • Dunn R.L.
        • Litwin M.S.
        • et al.
        Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
        Urology. 2000; 56: 899-905
        • Ware J.E.
        • Kosinski M.
        • Keller S.D.
        SF-12. 3rd ed. Quality Metric Incorporated, Lincoln, RI1998
        • Martinez A.A.
        • Pataki I.
        • Edmundson G.
        • et al.
        Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer.
        Int J Radiat Oncol Biol Phys. 2001; 49: 61-69
        • Sohayda C.
        • Kupelian P.A.
        • Levin H.S.
        • et al.
        Extent of extracapsular extension in localized prostate cancer.
        Urology. 2000; 55: 382-386
        • Davis B.J.
        • Pisansky T.M.
        • Wilson T.M.
        • et al.
        The radial distance of extraprostatic extension of prostate carcinoma.
        Cancer. 1999; 85: 2630-2637
        • Logue J.P.
        • Cowan R.A.
        • Hendry J.H.
        Hypofractionation for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2001; 49: 1522-1523
        • Zelefsky M.J.
        • Leibel S.A.
        • Kutcher G.J.
        • et al.
        Three-dimensional conformal radiotherapy, and dose escalation.
        Semin Radiat Oncol. 1998; 8: 107-114
        • Zelefsky M.J.
        • Fuks Z.
        • Wolfe T.
        • et al.
        Locally advanced prostatic cancer.
        Radiology. 1998; 209 ([In Process Citation]): 169-174


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.